Anjeso FDA Approval History
Last updated by Judith Stewart, BPharm on March 30, 2020.
FDA Approved: Yes (First approved February 20, 2020)
Brand name: Anjeso
Generic name: meloxicam
Dosage form: Injection
Company: Baudax Bio, Inc.
Treatment for: Pain
Anjeso (meloxicam) is a non-steroidal anti-inflammatory drug (NSAID) injection indicated for use in adults for the management of moderate-to-severe pain, alone or in combination with non-NSAID analgesics.
- Anjeso is administered as a once-a-day intravenous (IV) bolus push.
- The Anjeso product label carries a boxed warning that advises of the increased risk of serious cardiovascular thrombotic events (including myocardial infarction and stroke) and serious gastrointestinal (GI) adverse events (including bleeding, ulceration, and perforation of the stomach or intestines).
- Common adverse reactions include constipation, increased gamma-glutamyl transferase, and anemia.
Development timeline for Anjeso
| Date | Article |
|---|---|
| Feb 20, 2020 | Approval FDA Approves Anjeso (meloxicam injection) for the Management of Moderate to Severe Pain |
| Oct 31, 2019 | FDA Grants Appeal to Recro Pharma for IV Meloxicam New Drug Application |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
